Which tech monitors lurbinectedin's adverse reactions?

What clinical trials are tracking adverse reactions to lurbinectedin?

Several trials are monitoring adverse reactions to lurbinectedin, including [1] a phase I/II study investigating its safety and efficacy in treating various cancers. The trial evaluates multiple doses and treatment schedules, with a focus on adverse event monitoring using the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE).

Who is tracking lurbinectedin's safety profile?

The European Medicines Agency (EMA) is monitoring lurbinectedin's safety profile through postmarketing surveillance. The EMA recommends regular monitoring of adverse reactions, including those not previously reported, to ensure the drug's safety profile is as up-to-date as possible [2].

What organizations are collecting clinical data on lurbinectedin-related side effects?

The National Institute of Health's ClinicalTrials.gov database contains information on clinical trials involving lurbinectedin, including those that track adverse reactions [3]. Additionally, the FDA receives reports of adverse reactions to lurbinectedin through its Adverse Event Reporting System (FAERS) [4].

Are there any registries or databases tracking lurbinectedin-related adverse reactions?

While there are no dedicated registries or databases specifically tracking lurbinectedin-related adverse reactions, the FDA's FAERS and the EMA's EudraVigilance databases are critical in monitoring and reporting adverse events associated with the treatment [5].

Sources:
[1] ClinicalTrials.gov. (n.d.).

[2] European Medicines Agency. (n.d.).

[3] ClinicalTrials.gov. (n.d.).

[4] FDA. (n.d.).

[5] European Medicines Agency. (n.d.).

Cited Sources:
1. ClinicalTrials.gov. (n.d.).
2. European Medicines Agency. (n.d.).
3. ClinicalTrials.gov. (n.d.).
4. FDA. (n.d.).
5. European Medicines Agency. (n.d.).